Bleomycin a2

Base Information

• Chemical Name: Bleomycin a2
• CAS No.: 11056-06-7
• Deprecated CAS: 1247874-09-4,69215-21-0,754126-85-7
• Molecular Weight: 2927.17
• European Community (EC) Number: 232-925-2,234-356-5,689-127-6
• DSSTox Substance ID: DTXSID20872327
• Nikkaji Number: J25.633A
• Wikipedia: Bleomycin
• Wikidata: Q26841044
• NCI Thesaurus Code: C311,C313,C312
• RXCUI: 1621,1622
• Metabolomics Workbench ID: 133738
• ChEMBL ID: CHEMBL403664
• Mol file: 11056-06-7.mol

Synonyms:Bellon, Bléomycine;Bléomycine Bellon;Blanoxan;Blenoxane;BLEO cell;BLEO-cell;BLEOcell;Bleolem;Bleomicina;Bleomycin;Bleomycin A(2);Bleomycin A2;Bleomycin B(2);Bleomycin B2;Bleomycin Sulfate;Bleomycins;Bleomycinum Mack;Mack, Bleomycinum;Sulfate, Bleomycin

Chemical Property of Bleomycin a2

Chemical Property:

• Appearance/Colour: powder
• PSA: 794.66000
• LogP: -1.89040
• Storage Temp.: 2-8°C
• Solubility.: H2O: 20 mg/mL
• Water Solubility.: Soluble
• XLogP3: -7.5
• Hydrogen Bond Donor Count: 20
• Hydrogen Bond Acceptor Count: 31
• Rotatable Bond Count: 36
• Exact Mass: 1414.51898128
• Heavy Atom Count: 96
• Complexity: 2580

Purity/Quality:

99%, ^*data from raw suppliers

BLEOMYCIN 95.00% ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T
• Hazard Codes: T
• Statements: 46-40
• Safety Statements: 53-36/37-45

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antineoplastic Agents
• Canonical SMILES: CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
• Isomeric SMILES: CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
• Recent ClinicalTrials: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
• Recent EU Clinical Trials: Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation (IRE-CaCl2, ECT and IRE) on quality of life and progression – free survival in patients with pancreatic cancer' (IREC).
• Recent NIPH Clinical Trials: International Clinical Trial of Low and Standard Risk Germ Cell Tumors; AGCT1531
• General Description: Bleomycin (also known as Bleo, Bleocin, NSC 125066, or Blenamax) is an antineoplastic antibiotic whose mechanism of action involves the formation of a redox-active iron complex that activates dioxygen, leading to DNA strand scission. The carbamoyl group attached to the axial ligand portion of a bleomycin model compound enhances the oxygen-activating ability of the Fe(II) complex and facilitates the reduction of the Fe(III) complex, thereby accelerating the redox cycle and improving its efficiency in oxygen activation. This modification highlights the importance of structural features in optimizing bleomycin's therapeutic activity.

Technology Process of Bleomycin a2

There total 1 articles about Bleomycin a2 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

→ bleomycin (11056-06-7,9041-93-4)

Guidance literature:

Refernces

Effect of the carbamoyl group attached to an axial ligand portion of a novel bleomycin model on a dioxygen activating reaction

10.1248/cpb.46.1635

This research investigates the effect of a carbamoyl group attached to an axial ligand portion of a novel bleomycin (BLM) model compound on its redox reaction and oxygen activating ability. The study aims to clarify the role of the carbamoyl group in the redox cycle of the Fe-BLM complex. The key chemicals used include a novel BLM model compound (II) with a diaminopropionamide (DAPA) moiety as the axial ligand and a lauryl group as the steric factor, iron(II) sulfate for forming the Fe complex, dioxygen for the redox reaction, and dithiothreitol (DTT) as a reducing agent. The researchers synthesized the model compound II and conducted kinetic studies using UV-Vis spectroscopy and EPR methods. They found that the presence of the carbamoyl group on the DAPA portion significantly enhances the oxygen activating ability of the Fe(II) complex and facilitates the reduction process of the resulting Fe(III) complex, indicating that the carbamoyl group plays a crucial role in accelerating the redox cycle and improving the oxygen activation efficiency of the Fe-BLM complex.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Please select Metric Ton KG G Pound L ML

Email:

Company name:

Valid Period:

Detailed Requirements:

• Sample
• MOQ
• GMP
• FDA
• Price
  FOB CIF CFR EXW
• Urgent purchase

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Remove

Submit

1

What can I do for you?
Get Best Price

Get Best Price for 11056-06-7 Bleomycin

Send

Send

Metric Ton KG G Pound L ML

Send

Send